Patents by Inventor David Helton

David Helton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF EXPOSURE TO CHLORINE GAS WITH SCOPOLAMINE
    Publication number: 20220000881
    Abstract: Exposure of a subject to chlorine gas is treated by administering scopolamine to the subject.
    Type: Application
    Filed: October 31, 2019
    Publication date: January 6, 2022
    Inventor: David Helton
  • TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH OCINAPLON
    Publication number: 20200188403
    Abstract: A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a pyrazolopyrimidine compound such as ocinaplon, zaleplon, indiplon, or divaplon.
    Type: Application
    Filed: October 7, 2019
    Publication date: June 18, 2020
    Inventors: David Helton, Ernest Pfadenhauer
  • Emesis treatment
    Patent number: 10646457
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: May 12, 2020
    Assignee: REPURPOSED THERAPEUTICS, INC
    Inventors: David Helton, James Lucot
  • EMESIS TREATMENT
    Publication number: 20190231714
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Application
    Filed: February 6, 2019
    Publication date: August 1, 2019
    Inventors: David Helton, James Lucot
  • Emesis treatment
    Patent number: 10206889
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 19, 2019
    Assignee: REPURPOSED THERAPEUTICS, INC.
    Inventors: David Helton, James Lucot
  • EMESIS TREATMENT
    Publication number: 20180161287
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: David Helton, James Lucot
  • Emesis treatment
    Patent number: 9918949
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 20, 2018
    Assignee: Repurposed Therapeutics, Inc.
    Inventors: David Helton, James Lucot
  • EMESIS TREATMENT
    Publication number: 20150005388
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 1, 2015
    Inventors: David Helton, James Lucot
  • HETEROARYLTHIO DERIVATIVES AND ANALOGUES
    Publication number: 20130289047
    Abstract: Heteroarylthio compounds covalently linked to an arylpiperazine moiety for the treatment of neurological conditions.
    Type: Application
    Filed: October 14, 2011
    Publication date: October 31, 2013
    Applicant: EPIOMED THERAPEUTICS, INC.
    Inventors: David Helton, David Fick
  • EMESIS TREATMENT
    Publication number: 20120208892
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino) tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino) tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 16, 2012
    Applicant: EPIOMED THERAPEUTICS, INC.
    Inventors: David Helton, James Lucot
  • Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives
    Publication number: 20120070385
    Abstract: The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.
    Type: Application
    Filed: September 27, 2011
    Publication date: March 22, 2012
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Alvin J. Glasky, David B. Fick, David Helton
  • USE OF CYPROHEPTADINE TO TREAT ORGANOPHOSPHATE EXPOSURE
    Publication number: 20120065194
    Abstract: A method of treating exposure to an organophosphate compound by administering a cyproheptadine compound to a subject in need thereof.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Inventors: David HELTON, David FICK
  • TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS
    Publication number: 20110294823
    Abstract: Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder.
    Type: Application
    Filed: August 10, 2011
    Publication date: December 1, 2011
    Inventors: David HELTON, David FICK, Ernest PFADENHAUER
  • TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
    Publication number: 20110172242
    Abstract: A method of treating exposure to organophosphate agents through the use of compounds comprising tetrahydroindolone and arylpiperazine moieties.
    Type: Application
    Filed: October 14, 2010
    Publication date: July 14, 2011
    Inventors: David HELTON, David FICK
  • TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS
    Publication number: 20100305141
    Abstract: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.
    Type: Application
    Filed: August 6, 2010
    Publication date: December 2, 2010
    Inventors: David Helton, Daivd Fick, Ernie Pfadenhauer, Jason Sharp
  • TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
    Publication number: 20090264443
    Abstract: A method of treating exposure to organophosphate agents through the use of compounds comprising tetrahydroindolone and arylpiperazine moieties.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 22, 2009
    Inventors: David HELTON, David FICK
  • METHODS FOR TREATING COGNITIVE /ATTENTION DEFICIT DISORDERS USING TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES
    Publication number: 20090192319
    Abstract: Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.
    Type: Application
    Filed: March 30, 2009
    Publication date: July 30, 2009
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Alvin J. Glasky, David B. Fick, David Helton
  • TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS
    Publication number: 20090156609
    Abstract: Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 18, 2009
    Inventors: David Helton, David Fick, Ernest Pfadenhauer
  • Tetrahydroindolone Derivatives for Treament of Neurological Conditions
    Publication number: 20070208030
    Abstract: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.
    Type: Application
    Filed: September 27, 2004
    Publication date: September 6, 2007
    Applicant: Abraxis BioScience, Inc.
    Inventors: David Helton, David Fick, Ernest Pfadenhauer, Jason Sharp
  • Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
    Patent number: 6982269
    Abstract: Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: January 3, 2006
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Alvin J. Glasky, David B. Fick, David Helton